First Personal Financial Services Raises Stock Position in Johnson & Johnson (NYSE:JNJ)

First Personal Financial Services boosted its position in Johnson & Johnson (NYSE:JNJ) by 61.9% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,802 shares of the company’s stock after purchasing an additional 2,600 shares during the quarter. First Personal Financial Services’ holdings in Johnson & Johnson were worth $994,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also recently bought and sold shares of the company. GUNN & Co INVESTMENT MANAGEMENT INC. increased its position in shares of Johnson & Johnson by 1,194.9% in the fourth quarter. GUNN & Co INVESTMENT MANAGEMENT INC. now owns 237,273 shares of the company’s stock worth $37,190,000 after purchasing an additional 218,949 shares during the last quarter. Heritage Financial Services LLC increased its holdings in shares of Johnson & Johnson by 1.8% in the 4th quarter. Heritage Financial Services LLC now owns 10,269 shares of the company’s stock worth $1,609,000 after buying an additional 177 shares during the last quarter. Citizens Financial Group Inc. RI raised its position in shares of Johnson & Johnson by 4.8% during the 4th quarter. Citizens Financial Group Inc. RI now owns 107,589 shares of the company’s stock valued at $16,863,000 after buying an additional 4,954 shares in the last quarter. Gilliland Jeter Wealth Management LLC purchased a new position in Johnson & Johnson in the fourth quarter worth $2,467,000. Finally, Addison Advisors LLC grew its position in Johnson & Johnson by 5.9% in the fourth quarter. Addison Advisors LLC now owns 8,903 shares of the company’s stock worth $1,395,000 after acquiring an additional 494 shares in the last quarter. 69.55% of the stock is owned by institutional investors.

Johnson & Johnson Trading Up 1.0 %

Shares of Johnson & Johnson stock traded up $1.63 during trading on Friday, reaching $165.86. 7,441,042 shares of the stock were exchanged, compared to its average volume of 7,271,470. The company has a quick ratio of 0.85, a current ratio of 1.07 and a debt-to-equity ratio of 0.44. The firm has a market cap of $399.17 billion, a price-to-earnings ratio of 10.34, a price-to-earnings-growth ratio of 2.63 and a beta of 0.52. Johnson & Johnson has a 1 year low of $143.13 and a 1 year high of $165.98. The stock’s fifty day moving average is $155.34 and its 200 day moving average is $153.45.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Wednesday, July 17th. The company reported $2.82 earnings per share for the quarter, topping the consensus estimate of $2.71 by $0.11. Johnson & Johnson had a return on equity of 36.60% and a net margin of 46.34%. The business had revenue of $22.45 billion during the quarter, compared to analysts’ expectations of $22.33 billion. During the same quarter last year, the business posted $2.80 EPS. The business’s revenue was up 4.3% on a year-over-year basis. As a group, equities research analysts expect that Johnson & Johnson will post 10.07 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 10th. Shareholders of record on Tuesday, August 27th will be issued a $1.24 dividend. The ex-dividend date is Tuesday, August 27th. This represents a $4.96 annualized dividend and a yield of 2.99%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 30.92%.

Analysts Set New Price Targets

Several equities research analysts have issued reports on the company. Sanford C. Bernstein lifted their price target on Johnson & Johnson from $161.00 to $171.00 in a research note on Thursday, July 18th. TD Securities cut their target price on Johnson & Johnson from $195.00 to $185.00 in a research note on Thursday, July 18th. Daiwa America downgraded shares of Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 23rd. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $215.00 price objective on shares of Johnson & Johnson in a research note on Monday, August 5th. Finally, Daiwa Capital Markets cut shares of Johnson & Johnson from an “outperform” rating to a “neutral” rating and decreased their target price for the stock from $160.00 to $150.00 in a research report on Tuesday, July 23rd. Seven investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $173.21.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.